Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial.

ABSTRACT:

Background

Unravelling the performance of disease activity measures in peripheral spondyloarthritis (pSpA) is crucial for the development of clinical studies. We aimed to evaluate the construct validity and discriminatory capacity of various instruments assessing disease activity and response criteria in patients with pSpA.

Methods

Post-hoc analysis of the CRESPA randomised controlled trial including patients with early active pSpA. Patients were randomised to golimumab (GOL) or placebo (PBO). Data of the placebo-controlled part until week 12 were used. Construct validity (known group discrimination assessed with standardised mean difference, SMD) in the 12-week data, longitudinal construct validity (ie, standardised response mean and effect size) and trial discrimination (S

SUBMITTER: Lopez-Medina C 

PROVIDER: S-EPMC12265824 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature